Company Overview of Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products for customers worldwide. Its products include S-1, an oral antimetabolite and a combination of pharmacological compounds; ABI-007(Abraxane, a human serum albumin-bound paclitaxel; TSU-68, an orally administered, small-molecule, multiple receptor tyrosine kinase inhibitor; TAS-102, a novel combination antitumor agent; TAS-118, an antimetabolite solution; and ET-743(trabectedine), a synthetic derivative of a substance extracted from the colonial tunicate ecteinascidia turbinata. Its products also comprise TAS-114, an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism; TAS-115, ...
Founded in 1963
Key Executives for Taiho Pharmaceutical Co., Ltd.
President and Representative Director
Chief Executive Officer of Otsuka Holdings Co., Ltd., President of Otsuka Holdings Co., Ltd. and Representative Director of Otsuka Holdings Co., Ltd.
Head of Production Division - Cmc Center and Director
Compensation as of Fiscal Year 2016.
Taiho Pharmaceutical Co., Ltd. Key Developments
X-Chem, Inc. Announces Multi-Target Drug Discovery Collaboration with Taiho Pharmaceutical Using DEX Technology
Dec 20 16
X-Chem, Inc. announced that it entered into a multi-target drug discovery collaboration with Taiho Pharmaceutical Co. Ltd. This collaboration will grant Taiho access to X-Chem’s DEX™ technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The aim of the collaboration is to discover innovative lead structures for complex drug targets in multiple therapeutic areas with unmet medical need. Under the terms of this new agreement, X-Chem will receive an up-front payment as well as potential pre-clinical, clinical and regulatory milestone payments and sales milestones, up to a total of $352 million. Taiho has an exclusive option to license any programs generated in the course of the collaboration. X-Chem will also receive royalties for each successfully commercialized drug that results from a licensed collaboration program.
Taiho Pharmaceutical Co., Ltd. Announces the Launch of Bilanoa Tablets 20 Mg
Nov 18 16
Taiho Pharmaceutical Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced the launch of Bilanoa Tablets 20 mg (generic name: bilastine), an oral anti-allergy drug, in Japan. This product is an second-generation anti-histamine product, discovered by Faes Farma S.A. in Spain. Taiho has further developed the drug after signing a license agreement with Faes Farma in July 2012 for the development and marketing rights in Japan. In September 2016, Taiho received approval to manufacture and market the drug for the indications of allergic rhinitis, urticaria, and itching resulting from skin diseases (eczema/dermatitis and cutaneous pruritus). It has been approved in over 100 countries and regions and marketed by several partners under license from Faes Farma for the treatment of allergic rhinitis and urticaria.
Taiho Pharmaceutical Co., Ltd. Announces Establishment of Taiho Ventures, LLC
May 10 16
Taiho Pharmaceutical Co., Ltd. announced on May 10 that it has established Taiho Ventures, LLC, a strategic corporate venture capital arm of TPC, in California, USA. Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. With the support of Taiho's established expertise in the field of oncology product discovery and development, Taiho Ventures will provide financial resources and company outreach to build strategic alliances to help translate novel research and high-potential drug candidates into cornerstone products. Initially, Taiho Ventures will make investments from the pooled amount of $50 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|